A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM

What Was Tested

This registered phase 2 trial tested Semaglutide.

It had two arms (groups): one (experimental) and one (placebo comparator).

The registry classes the interventions as drug.

Who Took Part

It was open to people of any sex aged from 18 years up to 65 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Participant must be 18 to 65 years of age inclusive, at the time of signing the informed consent. Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. BMI between 27 kg/m2 and 40 kg/m2. Stable body weight (± 5 kg) within 90 days of screening, and body weight \<150 kg. Established diagnosis of T2DM.

The full record lists 14 inclusion and 26 exclusion criteria; among the exclusions: any prescription or over-the-counter medications intended for weight loss within 6 months of screening, excluding semaglutide; history of, or known hypersensitivity to, monoclonal antibody drugs or a contraindication to semaglutide (e.g. ozempic® or wegovy®); previous or current diagnosis of type 1 diabetes mellitus (t1dm) or current gestational diabetes.

How the Study Was Run

The set-up was randomized, parallel-group and triple-blind.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

As a double-blind Semaglutide study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant, care provider and investigator.

It started in 2026-01-06 with completion listed for 2026-01-23.

It ran at 1 site in United Arab Emirates.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Assess glycemic control using HbA1c (%). Assess weight loss using body weight measurements.

It also tracked 6 secondary outcomes, for example Assess the change in HbA1c (% point), Assess the change in body composition utilizing DEXA body scan, Assess the PK profile; AUC 0-inf, AUC 0-last, AUC tau, Cmax, tmax, t1/2, and Cl/F, Assess number of participants who experience Serious Adverse Events (SAEs), Assess number of participants who experience treatment emergent adverse events (TEAEs) and Assess number of participants who experience treatment related adverse events (TRAEs).

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Semaglutide in people.

It was withdrawn before enrolling anyone; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.